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Abstract 
Background: Salivary α-amylase (sAA) activity alternations are observed in major depressive disorder (MDD) 
being associated with depression severity and its specific psychopathological dimensions with anxiety being at-
tributed to distress. No data is available on sAA in MDD according to Hamilton Rating Scale for Depression 
(HAMD-17) and State-Trait Anxiety Inventory (STAI). The exploratory study examines whether and to what extent 
baseline sAA level is interrelated to the psychopathological features including severity of symptoms and specific 
psychopathological dimensions.
Material and Methods: The basal, non-stimulated sAA activity was studied in 20 non-late-life adult, treatment-naïve 
MDD patients with short-illness-duration and in 20 age- and sex-matched healthy controls along with psychometric 
assessments with Hamilton Rating Scale for Depression (HAMD-17) and Spielberger State-Trait Anxiety Inven-
tory (STAI). 
Results: Significantly lower (p=0.011) sAA activity was observed in MDD as compared to controls. No signifi-
cant correlations were observed between sAA activity and the total HAMD-17 score as well as with regard to the 
specific core depression, insomnia, anxiety and somatic HAM-D psychopathological dimensions.  No significant 
correlations were also found between sAA and STAIX-1 and STAIX-2 scores. 
Conclusions: Low baseline sAA levels in MDD with no correlations between sAA and psychopathological features 
including severity of symptoms and specific psychopathological dimensions was found.
Key words: Salivary alpha-amylase, major depressive disorder, Spielberger State-Trait Anxiety Inventory, Ham-
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Introduction
Major depressive disorder (MDD) is often associated 
with an altered monoamine neurotransmission accom-
panied by hypothalamic-pituitary-adrenal (HPA) axis 
dysfunction and autonomic nervous system (ANS) mal-
adaptive activation, being all associated with chronic 
stress. Salivary α-amylase (sAA) is adopted as a marker 
of autonomic activation and reflects central noradrener-
gic activity (1). It is sensitive to physiological stressors. 
Baseline sAA levels are significantly associated with 
chronic stress and stress reactivity in healthy individuals 
(1) with marked increases in sAA due to acute psycho-
logical stress and subjective anxiety reports. Changes in 
sAA were also seen in psychopathology, especially in 
anxiety-related disorders (2). 
It is hypothesised that the elevated sAA is present in 
MDD being indicative of an increased ANS activity. 
There is, however, considerable inconsistency in the 
results attributing sAA elevation to illness stage, seve-
rity, specific dimensions of depression and measures of 
distress (3,4). The elevated sAA activity was associated 
with depression severity and specific psychopathologi-
cal dimensions of MDD with anxiety being attributed 
to distress. STAI performance has been used as an indi-
cator of general anxiety, general psychological distress 
and general emotional distress. Nonetheless, systematic 
clinical data on sAA levels in MDD according to STAI 
profile are limited to a single study in 71 depressed pa-
tients where sAA levels were significantly increased in 
unremitted patients with MDD compared to both healthy 
controls and remitted patients with MDD. Still, STAI 
scores (State or Trait) were not associated with sAA le-
vel although STAI measurements in unremitted patients 
with MDD were significantly increased compared with 
healthy controls and remitted patients (3). Thus anxiety 
levels in MDD might not be associated with sAA or sa-
livary cortisol levels.
Recently we demonstrated low baseline sAA in drug-
naïve patients with short-illness-duration first episode 
MDD where sAA activity was not significantly corre-
lated neither with duration nor the severity of depressi-
ve symptoms as measured by the total HAMD-17 score 
(5). This exploratory study was undertaken to examine 
whether and to what extent sAA activity is interrelated 
to the psychopathological features of MDD including 
severity of symptoms and specific psychopathological 
dimensions in baseline non-stimulated conditions. It was 
hypothesized that the sAA elevation would be correlated 
with the measures of severity and distress in MDD in 
non-challenging and stress-free setting.  
Material and Methods
-Subjects
The study population has been described in detail el-
sewhere (5). Briefly, 20, first-episode drug-naïve MDD 
patients were recruited and diagnosed with the Structu-
red Clinical Interview for DSM-IV Axis I Disorders (6). 
The depression severity was rated with 17-item Hamil-
ton Rating Scale for Depression (HAMD-17) (7). Sub-
jects with HAMD-17 score of ≥20 and episode duration 
≤24 weeks were eligible. Anxiety was assessed with 
the Spielberger State-Trait Anxiety Inventory (STAI) 
(8). Exclusion criteria were: any other Axis I disorder, 
psychotic symptoms, suicidality, somatic comorbidity, 
history of oral health problems including salivary gland 
disorders, concomitant medication including dietary 
supplements, hormonal contraception, pregnancy/lacta-
tion, BMI ≤18 and ≥30, age <18 and >55 years. 
The control group consisted of 20 healthy subjects matched 
by age, sex, and metabolic parameters being naïve to psy-
chotropic drugs. They were interviewed with the Structu-
red Clinical Interview for DSM-IV, nonpatient edition (6). 
All subjects underwent routine physical examination and 
were administered STAI inventory (8). A HAMD-17 score 
≤5 was required for inclusion. None of them had a history 
of serious somatic disease or a family history of major psy-
chiatric illness in their first-degree relatives.
The study was performed in agreement with the Decla-
ration of Helsinki following the approval of the Ethic 
Research Committee of the Institution. For each study 
participant, written consent was obtained. 
-Procedure and measures
The study followed a case-control design. As previously 
described (5) saliva was sampled and processed with 
subsequent batch sAA activity analysis by means of an 
enzyme-linked immunoassay using an ELISA kit (Sali-
vary α-Amylase ELISA Kit, Salimetrics LLC, USA). 
The STAI results were analysed with regard to the diffe-
rentiation of the anxiety to anxiety caused by a specific 
condition (state subscale - STAIX-1), and anxiety as a 
more permanent characteristics of the personality (trait 
subscale - STAIX-2) (8). The total HAMD-17 score was 
analysed followed by the exploratory analysis based on 
the hierarchical Cole and Motivala model (9) with core 
depression, insomnia, anxiety and somatic psychopatho-
logical dimensions. 
-Statistical analysis
Statistical procedures were performed using StatsDirect 
v2.7.9. Shapiro-Wilk test was used to assess normal dis-
tribution of continuous data. Normally distributed va-
riables were compared using Student’s t-test, all other 
continuous data were compared with nonparametric 
Mann-Whitney U-test. The Spearman rank correlation 
coefficient was used to assess correlations between the 
obtained variables. All tests were two-tailed with an 
alpha=0.05.
Results
The sAA was significantly lower in MDD as compared 
to controls (p=0.011). Significantly higher STAIX-1 
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(p<0.0001) and STAIX-2 (p<0.0001) scores were obser-
ved in MDD as related to controls. There were no signi-
ficant differences in terms of gender, age, BMI or WHR 
between MDD patients and controls with none of these 
factors being significantly associated with sAA. Addi-
tional information can be found in prior reports (5,10).
The sAA in MDD subjects was not significantly corre-
lated neither with duration nor severity of depressive 
symptoms as measured by the total HAMD-17 score 
nor analysed psychopathological dimensions. No signi-
ficant correlations were found between sAA activity and 
STAIX-1 and STAIX-2 scores (Table 1).
Median (IQR) salivary Į-amylase 
R p
HAMD - total 22.5 (21, 24) 0.16 0.50 
Core depression 5 (5, 5) - 0.22 0.35 
Insomnia 3 (3, 4) 0.06 0.79 
Anxiety 7 (6, 7) 0.26 0.26 
Visceral 7 (6, 8) 0.09 0.71  
STAI-X1 54 (52, 58) - 0.20 0.39 
STAI-X2 48.5 (46.5, 50.5) 0.06 0.81 




Table 1: Pearson’s correlation coefficient between sAA activity and 
psychometric variables in MDD.
Discussion
Low baseline sAA was seen in depressed individuals as 
compared to controls. The depressive episode duration 
and global severity were not found to be significantly 
correlated with sAA activity as previously demonstrated 
(5). The results do not support the study hypothesis on 
the link between MDD and sAA elevation being correla-
ted with the measures of severity and distress in MDD.
The relationship between sAA level and stress is com-
plex. Salivary alpha-amylase is highly sensitive to phy-
siological stressors (2) and also psychosocial stress has 
been shown to lead to a prompt increase in sAA activity 
(11) with low durability of its stress induced increase ra-
pidly recovering to normal sAA levels after stress reduc-
tion in about 10 minutes. Interestingly, the momentary 
sAA levels are associated with high arousal affective 
states, regardless of emotional valence. Elevated mo-
mentary levels of sAA have also been associated with 
greater chronic stress (1,12).
The STAI consist two separate, self-report scales for 
measuring the distinct concepts of state and trait anxie-
ty. It is used as an indicator of general anxiety, general 
psychological distress and general emotional distress. 
State anxiety can measure the temporary and situatio-
nal anxiety state accompanied by autonomic excitement. 
The Trait scale assesses the tendency of an individual 
to respond to stressful circumstances under conditions 
of increased anxiety (8). To date, there are no investi-
gations that incorporated the use of baseline sAA levels 
and STAI to determine the relationship among distress, 
anxiety, and clinical characteristics in MDD.
In healthy subjects sAA activity is associated with sub-
jective anxiety reports (2). In self-report anxiety measure 
with STAI a high correlation between state anxiety mea-
sures and sAA release were found when subjects were 
exposed to aversive stimuli (2,13). Contrarily, a positive 
correlation among sAA activity, trait anxiety and subjec-
tive stress was also observed indicating the association 
between trait anxiety and sAA level (14).
Changes in sAA were demonstrated in psychopatholo-
gy, particularly in anxiety-related disorders (2). Scarce 
data on baseline sAA as related to depressive psychopa-
thology exist. In a study by Wingenfeld et al. (15) nei-
ther depression nor trait anxiety or perceived stress did 
influence sAA activity in questionnaire data. The sole 
systematic study on sAA levels in MDD according to 
STAI profile in a population of 71 depressed patients re-
vealed significantly increased sAA levels in unremitted 
patients with MDD compared to both healthy controls 
and remitted MDD patients. Still, STAI (State or Trait) 
and HAMD-17 scores were not correlated with sAA le-
vel although STAI measurements in unremitted patients 
with MDD were significantly increased compared with 
healthy controls and remitted patients (3).
The results corroborate with the paper by Ishitobi et al. 
(3) indicating specificity of MDD where anxiety levels 
in depressed states might not be associated with sAA le-
vel. It may be hypothesized that STAI measures are not 
associated with basal, non-stimulated sAA activity as its 
secretion occurs in response to acute stress. These re-
J Clin Exp Dent. 2017;9(4):e527-30.                                                                                                                    Salivary alpha-amylase STAI scores and depression psychopathology
e530
sults imply that the level of sAA is associated with MDD 
as the condition rather than distress (5).
Certain study limitations exist as the explorative study 
design with the observed associations does not represent 
causal relationships between the investigated parameters 
and may considerably contribute to the observed results 
that apply to drug-naïve patients with short-illness-du-
ration first episode MDD who were free of comorbid 
Axis I and II conditions, current suicidality and suicide 
history.
Conclusions
In conclusion, in basal, non-stimulated conditions low 
morning baseline sAA levels were found in MDD with 
no correlations observed between sAA and core depres-
sion, insomnia, anxiety and somatic psychopathological 
dimensions nor STAIX-1 and STAIX-2 scores.
A cross-sectional analysis adds to the evidence linking 
sAA activity with psychopathology of MDD at the early 
stage of the disease, with no correlations between sAA 
and psychopathological features, including severity of 
symptoms and specific psychopathological dimensions.
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